Literature DB >> 19846904

p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.

Dora Bocangel1, Shiladitya Sengupta, Sankar Mitra, Kishor K Bhakat.   

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, reverses mutagenic and cytotoxic effects of O(6)-alkylguanine in DNA induced by chemotherapeutic N-alkyl N-nitrosourea and procarbazine type drugs by dealkylating the adduct. MGMT expression is down-regulated by wild-type p53 (WTp53) in human tumor cells. Here we report that p53 sequesters the Sp1 transcription factor to prevent its binding to the cognate cis elements in the MGMT promoter and thus inhibits MGMT expression. Sp1 overexpression abrogated the inhibitory effect of p53 on the MGMT promoter activity in a dose-dependent manner. Stable interaction of Sp1 with WTp53 was observed in HCT116 cells. Moreover, WTp53 overexpression reduced the binding of the nuclear extract to the Sp1 consensus sequence, even though recombinant p53 alone did not bind to the same sequence. Taken together, these results suggest that sequestration of Sp1 could be one of the mechanisms by which p53 negatively regulates MGMT expression, thus enhancing sensitivity of tumor cells to O(6)-alkylguanine generating drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846904      PMCID: PMC2814523     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  54 in total

1.  Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.

Authors:  K S Srivenugopal; J Shou; S R Mullapudi; F F Lang; J S Rao; F Ali-Osman
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.

Authors:  T Kanaya; S Kyo; K Hamada; M Takakura; Y Kitagawa; H Harada; M Inoue
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

Review 3.  BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis.

Authors:  B Kaina; K Ochs; S Grösch; G Fritz; J Lips; M Tomicic; T Dunkern; M Christmann
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

4.  Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.

Authors:  L Zhang; D Yu; M Hu; S Xiong; A Lang; L M Ellis; R E Pollock
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  Cooperative effects of genes controlling the G(2)/M checkpoint.

Authors:  T A Chan; P M Hwang; H Hermeking; K W Kinzler; B Vogelstein
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  Identification of the putative brain tumor antigen BF7/GE2 as the (de)toxifying enzyme microsomal epoxide hydrolase.

Authors:  R Kessler; M F Hamou; M Albertoni; N de Tribolet; M Arand; E G Van Meir
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

7.  Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.

Authors:  K K Bhakat; S Mitra
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

8.  Multifaceted resistance of gliomas to temozolomide.

Authors:  Dora B Bocangel; Sydney Finkelstein; S Clifford Schold; Kishor K Bhakat; Sankar Mitra; Demetrius M Kokkinakis
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

9.  Chaperone-dependent stabilization and degradation of p53 mutants.

Authors:  P Muller; R Hrstka; D Coomber; D P Lane; B Vojtesek
Journal:  Oncogene       Date:  2008-01-28       Impact factor: 9.867

10.  The p53 functional circuit.

Authors:  S Jin; A J Levine
Journal:  J Cell Sci       Date:  2001-12       Impact factor: 5.285

View more
  38 in total

1.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

2.  p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells.

Authors:  Mei-Juan Wang; Dong-Sheng Pei; Guo-Wei Qian; Xiao-Xing Yin; Qian Cheng; Lian-Tao Li; Hui-Zhong Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2011-05-25

3.  MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.

Authors:  Er Nie; Xin Jin; Weining Wu; Tianfu Yu; Xu Zhou; Zhumei Shi; Junxia Zhang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

4.  Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.

Authors:  Nadia Malkoun; Cyrus Chargari; Fabien Forest; Marie-Jeannette Fotso; Lysian Cartier; Pierre Auberdiac; Julie Thorin; Cécile Pacaut; Michel Peoc'h; Christophe Nuti; Thierry Schmitt; Nicolas Magné
Journal:  J Neurooncol       Date:  2011-07-02       Impact factor: 4.130

Review 5.  O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Authors:  John R Silber; Michael S Bobola; A Blank; Marc C Chamberlain
Journal:  Biochim Biophys Acta       Date:  2012-01-08

6.  Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53.

Authors:  Nathalia Meireles da Costa; Agnès Hautefeuille; Marie-Pierre Cros; Matias Eliseo Melendez; Timothy Waters; Peter Swann; Pierre Hainaut; Luis Felipe Ribeiro Pinto
Journal:  Cell Cycle       Date:  2012-11-19       Impact factor: 4.534

7.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

8.  Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Authors:  Ling Cen; Brett L Carlson; Jenny L Pokorny; Ann C Mladek; Patrick T Grogan; Mark A Schroeder; Paul A Decker; S Keith Anderson; Caterina Giannini; Wenting Wu; Karla V Ballman; Gaspar J Kitange; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2013-03-10       Impact factor: 12.300

9.  Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination.

Authors:  Hasan Caglar Ugur; Mehmet Taspinar; Seda Ilgaz; Fatma Sert; Hande Canpinar; Juan A Rey; Javier S Castresana; Asuman Sunguroglu
Journal:  Mol Biol Rep       Date:  2013-12-25       Impact factor: 2.316

10.  Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Nikolaos E Stathakis; George K Koukoulis; Christos N Papandreou
Journal:  Cell Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.